Cronos Group (CRON) Competitors

Cronos Group (NASDAQ:CRON) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Does the media prefer CRON or MLTX?

In the previous week, Cronos Group had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 2 mentions for Cronos Group and 1 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Cronos Group's score of 0.57 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CRON or MLTX more profitable?

Cronos Group has a net margin of 39.69% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.69%	-0.07%	-0.07%
MoonLake Immunotherapeutics	N/A	-30.81%	-28.40%

Which has preferable valuation & earnings, CRON or MLTX?

Cronos Group has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$117.61M	6.69	$41.08M	$0.13	15.69
MoonLake Immunotherapeutics	N/A	N/A	-$118.94M	-$2.30	-20.16

Which has more volatility and risk, CRON or MLTX?

Cronos Group has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Do analysts prefer CRON or MLTX?

MoonLake Immunotherapeutics has a consensus target price of $74.50, indicating a potential upside of 60.68%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MoonLake Immunotherapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in CRON or MLTX?

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 7.3% of Cronos Group shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cronos Group beats MoonLake Immunotherapeutics on 8 of the 15 factors compared between the two stocks.